Introduction
============

Gastric cancer (GC) is the third leading cause of cancer-related death worldwide and causes more than 723,000 deaths every year [@B1]. Despite recent therapeutic advances, the mortality of GC remains high due to its silent nature, late clinical presentation and high levels of biological and genetic heterogeneity [@B2]. GC is a heterogeneous disease that evolves in various genetic and epigenetic alterations [@B2]-[@B9], including transcriptional changes of noncoding RNAs.

MicroRNAs (miRNAs), a class of noncoding RNAs, regulates protein expression through incomplete base pairing with the 3\' untranslated regions (3\'UTR) of target messenger RNAs (mRNAs) [@B10]. Accumulating evidences suggest that miRNAs play an important role in GC development and progression. Though certain miRNAs, such as miR-21 [@B11], miR-148a [@B12], miR-218 [@B13] and miR-29c [@B14], have been confirmed to act as oncogenes or tumor suppressor genes in GC, there are many other miRNAs suggested to be dysregulated by microRNA arrays, of which the detailed molecular mechanisms in GC are still not well elucidated. MicroRNA-647 (miR-647) has been reported to be a predictive biomarker for prostate cancer recurrence and a prognostic factor for Taxol-sensitive ovarian cancer patients [@B15], [@B16]. It was also identified as one of the 7 population-differentiated-miRNAs that are currently implicated as cancer biomarkers or diagnostics [@B17]. Although miR-647 has been reported to be dysregulated in GC [@B18], [@B19], the molecular mechanism of miR-647 in cancer metastasis was not fully uncovered.

Here we report that miR-647 expression is repressed in GC. *In vitro*and *in vivo* restorations of miR-647 via exogenous transfection are sufficient to inhibit both GC cell migration and invasion. SRF, a transcription factor known to promote tumor metastasis, and MYH9, a well-known cytoskeleton, are direct and indirect downstream targets of miR-647, respectively. MiR-647/SRF/MYH9 axis is also strongly correlated with GC metastasis in patients. Importantly, we demonstrate that agomir-647, an engineered miRNA mimic, and CCG-1423, an inhibitor of the Rho/MKL1/SRF signaling [@B20], synergistically inhibit cancer metastasis in orthotropic GC models. Taken together, our results provide an explanation of the metastatic mechanism of GC, and might be novel therapeutic targets or prognostic markers for GC.

Materials and Methods
=====================

Patients and Specimens
----------------------

Two independent cohorts involving 199 GC patients were enrolled in this study. In cohort 1, fresh GC samples and adjacent noncancerous tissues were collected from 109 pathologically verified GC patients who underwent gastrectomy between November 2012 and November 2013 in Nanfang Hospital, Southern Medical University (Guangzhou, China). None of the patients received chemotherapy or radiotherapy before gastrectomy. The GC diagnosis was made by endoscopic biopsy combined with histopathological information after surgery. Diagnosis was confirmed by two pathologists in Nanfang hospital according to American Joint Committee on Cancer (AJCC) TNM Staging Classification for Carcinoma of the Stomach (7th ed., 2010) [@B21]. Most of cohort 1 patients were followed up for 3 years. This study was approved by the Ethics Committee of Nanfang hospital (Guangzhou, China). For cohort 2, a gastric adenocarcinoma tissue microarray (TMA, HStm-Ade180Sur-05; Shanghai Outdo Biotech) was obtained from the National Engineering Center For Biochip at Shanghai. The TMA was constructed with 90 paired formalin-fixed, paraffin-embedded gastric adenocarcinoma tissues and their corresponding adjacent normal tissues. Cohort 2 patients were followed up for 7.8 years. The corresponding clinicopathological information was listed in Table [S1](#SM1){ref-type="supplementary-material"}.

Cell Lines and Cell Culture
---------------------------

Human GC cell lines (MGC 80-3, MKN45, SNU-5, AGS and KATOIII) were purchased from the Cell Resource Center, Shanghai Institute of Biochemistry and Cell Biology at the Chinese Academy of Sciences. Cells were cultured in RPMI-1640 medium (MGC 80-3 and MKN45), F12 (AGS) or Dulbecco\'s Modified Eagle\'s Media (KATOIII and SNU-5) containing 10% fetal bovine serum (FBS) at 37°C in an atmosphere of 5% CO~2~.

*In Situ* Hybridization (ISH)
-----------------------------

All the paraffin sections were examined with locked nucleic acid (LNA) based ISH using DIG-labeled miRCURY miRNA probes (Exiqon, Vedbaek, Denmark). The protocol for detection of miRNAs has been previously published [@B22].

Statistical Analysis
--------------------

Statistical analysis was performed using GraphPad Prism software 5.0 (GraphPad Software, Inc., San Diego, CA, USA) and SPSS software (Version 21.0; Abbott Laboratories, Chicago, IL). Data were shown as mean ± standard error of mean unless otherwise noted. The Student*t* test was used to detect significance of data from qPCR experiments, migration and invasion assays, luciferase reporter assay, ChIP assay and *in vivo* metastatic nodules assay. Moreover, it was used to detect the relationship between miR-647 expression and clinicopathologic characteristics. Pathway enrichment analysis of miR-647 target genes was based on Fisher\'s exact test using a 2×2 contingency table. Mann-Whitney U test was used to analyze SRF protein expression between normal and GC tissues detected by IHC. The associations between miR-647 expression detected by ISH and proteins expression detected by IHC were analyzed by the χ^2^ test. Survival curves were calculated using Kaplan-Meier and log-rank tests. The effects of variables on survival were determined by univariate and multivariate Cox proportional hazards modeling. Correlation between SRF and MYH9 proteins in the TMA was analyzed by Spearman rank correlation, while correlation between SRF and MYH9 mRNA data extracted from TCGA was analyzed by Pearson correlation. A *p* value less than .05 was considered statistically significant.

All supplementary methods are available in *[supplementary material](#SM1){ref-type="supplementary-material"}*.

Results
=======

MiR-647 is downregulated in GC tissues and associated with GC metastasis
------------------------------------------------------------------------

To identify the expression of miR-647 in GC, we first detected its expression in 109 human GC tissues by qPCR. The result showed that miR-647 was frequently downregulated in GC tissues (T) compared to normal gastric mucosa (N) (p \<0.0001, Figure [1](#F1){ref-type="fig"}A). Moreover, 73.4% (80 of 109) of the GC had at least 2-fold reduced expression of miR-647 compared with their corresponding nontumorous tissues (Figure [1](#F1){ref-type="fig"}B), which was supported by data from GSE36968 (Figure [S1](#SM1){ref-type="supplementary-material"}A). To determine whether miR-647 expression levels were related to GC progression, we analyzed the association between miR-647 and clinicopathologic status in 109 GC patients (Table [S1](#SM1){ref-type="supplementary-material"}-2). As shown in Figure [1](#F1){ref-type="fig"}C and Table [S2](#SM1){ref-type="supplementary-material"}, statistical analysis represented a strong correlation between miR-647 expression and TNM stage (*p*=0.0020), lymph-node metastasis (*p*=0.0046) and local invasion (*p*=0.0062). Collectively, these findings strongly suggested that miR-647 was downregulated in GC and negatively associated with GC metastasis.

To detect the function of miR-647 in GC cell invasion and migration, we first determined the expression of miR-647 in 5 normal human gastric tissues from 109 gastric cancer patients, 5 human gastric cancer cell lines (MGC 80-3, MKN45, SNU-5, AGS and KATOIII) and 3 human colorectal cancer cell lines (SW480, SW620 and Caco2) available in our lab by qPCR. Since miR-647 had been identified as one of the 7 miRNAs that were implicated as cancer biomarkers or diagnostics for multiple cancers, including colorectal cancer [@B17], the human colorectal cancer cell lines were used as positive controls. The results showed miR-647 expression was relatively lower in GC cell lines compared with normal tissues (Figure [S2](#SM1){ref-type="supplementary-material"}A). Since miR-647 expression was lowest in MGC 80-3 among 5 GC cell lines, followed by MKN45 (Figure [1](#F1){ref-type="fig"}D), and AGS had relatively higher miR-647 expression level and lentivirus transfection efficiency, we chose MGC 80-3, MKN45 and AGS to establish miR-647 stably overexpressing cell lines by lentivirus infection. Successful overexpression or knockdown of miR-647 was confirmed by qPCR (Figure [1](#F1){ref-type="fig"}E-F). Intriguingly, overexpression of miR-647 significantly suppressed the migratory and invasive abilities of MGC 80-3 and AGS cells (Figure [1](#F1){ref-type="fig"}G-H and S2D). Simultaneously, knockdown of miR-647 expression in these LV-miR-647 GC cells by transiently transfecting miR-647 inhibitors could restore the migration and invasion of GC cells (Figure [1](#F1){ref-type="fig"}G-H and S2D).

MiR-647, associated with Rho Signaling Pathways, negatively regulates SRF and MYH9 expression in GC cells
---------------------------------------------------------------------------------------------------------

To identify how miR-647 was involved in GC metastasis, we firstly used 4 common miRNA target prediction engines (miRanda, TargetScan, miRDB, and miRWalk) to search for putative protein-coding gene targets of miR-647 (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk/micrornapredictedtarget.html>), and 7724 potential targets were found (Figure [2](#F2){ref-type="fig"}A). Since miR-647 significantly inhibited GC migration and invasion, we selected 26 genes, listed out in Figure [2](#F2){ref-type="fig"}A and Table [S3](#SM1){ref-type="supplementary-material"}, associated with GC metastasis in PubMed. Additionally, we performed pathway enrichment analysis of miR-647 target genes predicted in the miRBase Targets database (<http://microrna.sanger.ac.uk/targets>) using miRGator online software (<http://genome.ewha.ac.kr> miRGator) (Table [S4](#SM1){ref-type="supplementary-material"}) [@B23], [@B24]. Specifically, the analysis showed that miR-647 was associated with Rho cell motility signaling pathway (Figure [2](#F2){ref-type="fig"}B, *p*=0.0134, BioCarta) and Role of MAL in Rho-mediated activation of SRF (Figure [2](#F2){ref-type="fig"}B, *p*=0.0348, BioCarta), which were critical pathways synergistically promoting cancer cell migration and invasion [@B25]. Because Rho-mediated pathways are closely associated with cancer metastasis and frequently activated in GC [@B7], [@B26], we selected out 5 candidate genes (SRF, ROCK1, ZAK, ELMO2, and MYH9) from Figure [2](#F2){ref-type="fig"}A (red marked) for further research, which were reported to be up-regulated in GC or associated with Rho-ROCK and Rho-MRTF/SRF pathways [@B12], [@B27]-[@B30].

Since MGC 80-3 and MKN45 expressed miR-647 at relatively low level, AGS and SNU-5 expressed miR-647 at relatively high level (Figure [1](#F1){ref-type="fig"}D), we transfected MGC 80-3 and MKN45 with miR-647 mimics, AGS and SNU-5 with miR-647 inhibitors (Figure [S2](#SM1){ref-type="supplementary-material"}E). Then, we carried out qPCR to detect these genes in transfected cells. The results revealed that the expression levels of SRF mRNA were most downregulated in MGC 80-3 and MKN45 cells treated with miR-647 mimics, followed by MYH9 and ZAK mRNAs (Figure [2](#F2){ref-type="fig"}C and S2F). Consistently, these three mRNAs were upregulated in AGS and SNU-5 cells treated with miR-647 inhibitors (Figure [2](#F2){ref-type="fig"}C and S2G). Because the fold changes of SRF and MYH9 mRNAs in miR-647-dysregulated GC cells are the highest, we focused on these two genes and carried out western blot and qPCR to confirm their relationship with miR-647. As showed in Figure [2](#F2){ref-type="fig"}D-E and S2B-C, the expression levels of SRF and MYH9 were both positively associated with miR-647 expression between GC cell lines and normal tissues. Moreover, we detected SRF and MYH9 proteins in GC cell lines stably overexpressing miR-647 (MGC 80-3-LV-miR-647, MKN45-LV-miR-647 and KATOIII-LV-miR-647) by western blot. The results showed SRF and MYH9 levels were significantly downregulated in the case of miR-647 overexpression (Figure [2](#F2){ref-type="fig"}F, S2H and S2J). In addition, when we transfected MGC 80-3-LV-miR-647, MKN45-LV-miR-647 and SNU-5 with miR-647 inhibitors, the expression of SRF and MYH9 proteins significantly restored (Figure [2](#F2){ref-type="fig"}G, S2I and S2J). Taken together, these results supported that miR-647 was negatively associated with SRF and MYH9 expression levels.

MiR-647 inhibits the migration and invasion of GC cell lines by directly targeting to SRF mRNA, and indirectly regulating MYH9 expression
-----------------------------------------------------------------------------------------------------------------------------------------

We performed luciferase reporter assays to determine whether miR-647 directly interacts with the 3\'UTR of SRF and MYH9 mRNAs. Using a computer-based sequence analysis (TargetScan and miRanda), we acquired potential miR-647-targeting sequences of SRF and MYH9. As shown in Figure [3](#F3){ref-type="fig"}A, three potential binding sites of miR-647 were located in 3\'UTR of SRF, while one potential binding site in 3\'UTR of MYH9. Then, we subcloned two 235-bp fragments of the SRF 3\'UTR (Figure [3](#F3){ref-type="fig"}A; position 19-253 and 1152-1386, marked as WT1 and WT2) that included all the three predicted miR-647 recognition sites (Figure [3](#F3){ref-type="fig"}A; position 122-128, 150-155 and 1260-1271), and their corresponding mutant counterparts (Figure [3](#F3){ref-type="fig"}A; Mut1-3) into a luciferase reporter plasmid (pGV306). For testing whether SRF was a direct target of miR-647, MGC 80-3 and AGS cells were cotransfected with miR-647 mimics (or a negative control) and luciferase vectors containing wild type SRF-3\'UTR (WT1 and WT2) (or luciferase vectors containing mutant-type SRF-3\'UTR (Mut1-3)). Similarly, for determining whether miR-647 directly interacted with the MYH9 mRNA, we subcloned a 203-bp fragment of the MYH9 3\'UTR (Figure [3](#F3){ref-type="fig"}A; position 732-934, marked as WT3) that included the predicted miR-647 recognition site (Figure [3](#F3){ref-type="fig"}A; position 832-837), and inserted it or its corresponding mutant counterpart (Mut4) into pGV306. Then, MGC 80-3 and AGS cells were cotransfected with miR-647 mimics (or a negative control) and luciferase vector containing wild type MYH9-3\'UTR (WT3) (or luciferase vector containing mutant-type MYH9-3\'UTR (Mut4)). As shown in Figure [3](#F3){ref-type="fig"}B, in cells transfected with WT SRF-3\'UTR (WT1 or WT2) vectors and the miR-647 mimics, a significant decrease in luciferase activity was observed compared with cells cotransfected SRF-3\'UTR vectors and negative controls. However, the luciferase activity of mutant-type SRF-3\'UTR vectors (Mut1 and Mut3), excepting for Mut2, did not change following cotransfection with the miR-647 mimics, indicating miR-647 could directly interact with two sequences (GCAGCCA and UGAGUGCAGCCA) within SRF 3\'UTR (Figure [3](#F3){ref-type="fig"}B). In GC cells (MGC 80-3 and AGS) transfected with WT MYH9-3\'UTR (WT3) vector and the miR-647 mimics, no significant change in luciferase activity was observed compared with WT3 vector and negative controls (Figure [3](#F3){ref-type="fig"}C). And the luciferase activity of mutant-type MYH9-3\'UTR vectors (Mut4) also did not change following cotransfection with the miR-647 mimics (Figure [3](#F3){ref-type="fig"}C). Collectively, these findings suggested miR-647 could directly target to the 3\'UTR of SRF, but not the 3\'UTR of MYH9.

To understand why MYH9 expression was indirectly associated with miR-647, we analyzed the 1-kb region directly upstream of MYH9 and predicted potential transcriptional factors (TFs) by using bioinformatics analysis websites (Proscan and JASPAR) (Figure [3](#F3){ref-type="fig"}D). We generated the full-length MYH9 promoter construct (luciferase plasmid construct) pGL3-MYH9-1300 (wild-type) and five truncation constructs (pGL3-MYH9-1000, pGL3-MYH9-903, pGL3-MYH9-753, pGL3-MYH9-528 and pGL3-MYH9-328) according to the locating sites of predicted TFs (Figure [3](#F3){ref-type="fig"}D). Intriguingly, dual-luciferase reporter assay showed that position -589 to -439, which potentially contained SRF binding site (CCATATATGG), was found to significantly increase the relative luciferase activity (Figure [3](#F3){ref-type="fig"}D). SRF was a ubiquitously expressed, pleiotropic transcription factor that activated genes by targeting to CArG box, which was a 10-bp CC (A+T-rich)~6~GG DNA sequence [@B31]. To further confirm this binding site, we constructed pGL3-MYH9-903-mut, which contained CArG box-mutant sequence (AACGACCAGAG). Luciferase reporter assay showed a significant decrease in reporter activity of MGC 80-3 cells cotransfected with pGV311-SRF and pGL3-MYH9-903-mut (Figure [3](#F3){ref-type="fig"}E), compared with MGC 80-3 cells cotransfected with pGV311-SRF and pGL3-MYH9-903. ChIP-qPCR analysis was further performed on MGC 80-3 and AGS cells. RNA polymerase II (RNAPII), which binds to the GAPDH promoter, was used as a positive control. The fold enrichment over the IgG control was represented. MYH9 promoter sequences were specifically enriched by anti-SRF and anti-MRTFA antibodies (a coactivator of SRF; Myocardin-related transcription factor A), but not by negative control antibody IgG in both MGC 80-3 and AGS cells (Figure [3](#F3){ref-type="fig"}F and Figure [S3](#SM1){ref-type="supplementary-material"}A). These data suggested that MYH9 was a direct target of transcriptional factor SRF in GC cells (Figure [3](#F3){ref-type="fig"}G). To detect whether SRF-MYH9 axis contributed to miR-647-associated GC metastasis, we transfected MGC 80-3/AGS-LV-miR-647 with SRF or MYH9 plasmids, followed by puromycin or G418 selections. Western blot analysis showed that upregulation of SRF in MGC 80-3/AGS-LV-miR-647 restored SRF and MYH9 expression, while overexpression of MYH9 in these cells only contributed to MYH9 upregulation (Figure [3](#F3){ref-type="fig"}H). Cell 3D migration and invasion assays suggested that the migratory and invasive abilities of MGC 80-3/AGS-LV-miR-647 restored after being transfected with either SRF or MYH9 plasmids (Figure [3](#F3){ref-type="fig"}I and S3B). Taken together, miR-647 could inhibit the migration and invasion of GC cell lines by targeting SRF/MYH9 signaling pathway.

MiR-647 is associated with poor prognosis and negatively related with SRF and MYH9 expression in GC patients
------------------------------------------------------------------------------------------------------------

To determine whether there was an association between the expression levels of miR-647 and its target SRF in human GC tissues, we firstly analyzed the data from GEO database. Analysis of GSE36968 showed that miR-647 expression tended to be negatively associated with SRF mRNA (r~s~=-0.2982; *p*=0.2293; Figure [S1](#SM1){ref-type="supplementary-material"}B) and MYH9 mRNA (r~s~=-0.5273; *p*=0.0245; Figure [S1](#SM1){ref-type="supplementary-material"}B), although the correlation between miR-647 and SRF mRNA was not significant. To further verify the correlations, we detected the SRF and MYH9 expression of GC tissues and their matched normal mucosa in 52 GC patients from cohort 1 by qPCR. The results showed that both SRF and MYH9 mRNAs were significantly upregulated in GC tissues (Figure [S1](#SM1){ref-type="supplementary-material"}C), which was supported by GSE63288 (Figure [S1](#SM1){ref-type="supplementary-material"}D), and their expressions were negatively associated with miR-647 expression detected by qPCR and IHC (Figure [S1](#SM1){ref-type="supplementary-material"}E-F). Since our studies*in vitro* suggested miR-647 indirectly regulated MYH9 expression, the negative correlation between miR-647 and MYH9 mRNA could be attributed to dysregulation of SRF protein by miR-647. To confirm the relation between miR-647 expression and SRF protein levels, we further detected the SRF protein expression in 109 GC patients and their corresponding nontumorous tissues by IHC. The results showed that SRF protein was significantly upregulated in GC (Figure [4](#F4){ref-type="fig"}A and [4](#F4){ref-type="fig"}B), and high expression of SRF protein was more likely to be seen in GC with low levels of miR-647 (data from qPCR) (Figure [4](#F4){ref-type="fig"}C), suggesting that the upregulation of SRF protein mainly resulted from repression of miR-647 in GC. Furthermore, we detected the expression of miR-647 by ISH (Figure [4](#F4){ref-type="fig"}D). It was also found that miR-647 levels were negatively correlated with the levels of SRF and MYH9 protein (Figure [4](#F4){ref-type="fig"}E and [4](#F4){ref-type="fig"}F). Low miR-647 expression was significantly associated with higher histological grade (*p*=0.028), deeper local invasion (*p*=0.001), lymph-node metastasis (*p*=0.000) and advanced clinical stage (*p*=0.024) in Table [S5](#SM1){ref-type="supplementary-material"}. Kaplan-Meier analysis revealed that low-level expression of miR-647 was associated with poor overall survival in GC patients (*p*=0.024; Figure [4](#F4){ref-type="fig"}G). A multivariate Cox regression analysis indicated that low-level expression of miR-647 was an independent prognostic factor for predicting poor survival of GC (Table [1](#T1){ref-type="table"}).

Activated SRF/MYH9 axis promotes GC metastasis and is associated with poor prognosis in GC
------------------------------------------------------------------------------------------

Since miR-647 could inhibit GC cell metastasis by SRF/MYH9 axis *in vitro*, we further detected the activity of this axis in GC. Firstly, we transfected MGC 80-3 and MKN45 cells with 3 SRF siRNAs and found SRF siRNA2 as the most effective sequence for knocking down SRF expression in GC cell lines by western blot (Figure [S4](#SM1){ref-type="supplementary-material"}). Then, we constructed a plasmid containing this sequence, marked as shRNA2, and transfected MGC 80-3 cells with it to obtain SRF knocked-down GC cells (MGC 80-3-SRF KD). Western blot and qPCR analysis showed that MYH9 expression in MGC 80-3-SRF KD significantly downregulated (Figure [5](#F5){ref-type="fig"}A). In addition, we further transfected MGC 80-3-SRF KD with a SRF plasmid, and found that both SRF and MYH9 expression were restored (Figure [5](#F5){ref-type="fig"}B), which further supported MYH9 was a downstream gene of SRF.

To test whether SRF/MYH9 axis regulated by Rho signaling pathway, we treated GC cells with CCG-1423, an inhibitor of RhoA/SRF-mediated gene transcription [@B32]. Firstly, we detected its IC50 in MGC 80-3 and AGS cells. The results showed that the IC50 of CCG-1423 in MGC 80-3 was 5.22 uM and in AGS was 5.08 μM (Figure [S5](#SM1){ref-type="supplementary-material"}A). In addition, before the function assays, GC cells (MGC 80-3 and AGS) were exposed to CCG-1423 with a linear concentration gradient, and 7.5uM CCG-1423 was found to be a better concentration due to its less toxic compared with 9uM in MGC 80-3 (Figure [S5](#SM1){ref-type="supplementary-material"}B). Intriguingly, we found that CCG-1423 effectively inhibited GC cells\' invasion and MYH9 expression (Figure [5](#F5){ref-type="fig"}C-D and S5C), which suggested that SRF/MYH9 axis in GC was mediated by RhoA signaling pathway. In addition, the dysregulation of SRF expression by directly targeting to SRF gene could change GC cells\' invasion. We also detected SRF and MYH9 expressions in GC cell lines (MKN45 and MGC 80-3) and GC tissues by confocal immunofluorescence microscopy. The results showed both proteins broadly located in cytoplasm and nucleus of GC cells (Figure [5](#F5){ref-type="fig"}E).

To further investigate the clinicopathological and prognostic significance of SRF and MYH9 in GC patients, we analyzed two GC cohorts by IHC, which included paired samples of normal gastric mucosa and GC tissues from 109 patients in our hospital (cohort 1) and National Engineering Center for Biochip in Shanghai (TMA; Figure [5](#F5){ref-type="fig"}F; cohort 2). High SRF expression was positively correlated with higher histological grade (*p*=0.031), deeper local invasion (*p*=0.016), lymph-node metastasis (*p*=0.000), distant metastasis (*p*=0.017) and advanced clinical stage (*p*=0.009) in cohort 1 (*p*\<0.05; Table [S6](#SM1){ref-type="supplementary-material"}), and positively correlated with lymph-node metastasis (*p*=0.032) in cohort 2 (*p*\<0.05; Table [S7](#SM1){ref-type="supplementary-material"}). Meanwhile, high MYH9 expression was positively related with lymph-node metastasis (*p*=0.000) and distant metastasis (*p*=0.042) in cohort 1 (*p*\<0.05; Table [S6](#SM1){ref-type="supplementary-material"}), and positively related with lymph-node metastasis (*p*=0.040), advanced clinical stage (*p*=0.043) and tumor location at antrum or whole stomach (*p*=0.038) in cohort 2 (*p*\<0.05; Table [S7](#SM1){ref-type="supplementary-material"}). Kaplan-Meier analysis showed that high levels of SRF and MYH9 expression were correlated with poor overall survival in both cohorts (Figure [5](#F5){ref-type="fig"}G and S6A-B). And miR-647, SRF and MYH9 expression levels were correlated with disease-free survival in cohort 1 (Figure [S6](#SM1){ref-type="supplementary-material"}C-E), respectively. Furthermore, multivariate Cox regression analysis revealed SRF and MYH9 expression to be an independent prognostic factor for poor survival (Table [1](#T1){ref-type="table"}). Moreover, the expression of MYH9 protein was positively correlated with the expression of SRF protein (Figure [5](#F5){ref-type="fig"}H and S6F-G), which was further supported by analysis of these two mRNAs\' expression data extracted from TCGA and GEO database (Figure [5](#F5){ref-type="fig"}I and S1Ga-c), and data detected by qPCR in 52 GC patients involved in cohort 1 (Figure [S1](#SM1){ref-type="supplementary-material"}Gd).

Ectopic expression of miR-647/SRF regulates tumor growth and metastasis by orthotropic implantation of GC *in vivo*
-------------------------------------------------------------------------------------------------------------------

To further explore the role of miR-647 on tumor metastasis *in vivo*, MGC 80-3 cells stably expressed LV-NC/vector, LV-miR-647/vector and LV-miR-647/SRF were transplanted subcutaneously into nude mice, and the growth of resultant primary tumors then was monitored. After growth to an average size of 1 cm^3^, tumors were orthotopically sutured to the stomach of nude mice (Figure [S7](#SM1){ref-type="supplementary-material"}) [@B33]. Mice were sacrificed at the humane end point at two months after operation. The results showed metastatic lesions in the intestine, liver and abdominal wall (Figure [6](#F6){ref-type="fig"}A). Among these three groups, the tumor volumes of LV-miR-647/vector group were significantly smaller than the control group (LV-NC/vector group), and the tumor volumes of LV-miR-647/SRF group were relatively bigger than the LV-miR-647/vector group (Figure [6](#F6){ref-type="fig"}B). Additionally, in the group of mice bearing tumors of MGC 80-3-LV-NC/vector cells (control group), 100% (7 of 7), 85.7% (6 of 7) and 71.4% (5 of 7) of mice had intestinal, hepatic and abdominal wall metastases, respectively (Figure [6](#F6){ref-type="fig"}C). However, in the group of mice bearing tumors of MGC 80-3-LV-miR-647/vector cells, 75% (6 of 8), 25% (2 of 8) and 25% (2 of 8) of mice had intestinal, hepatic and abdominal wall metastases, respectively (Figure [6](#F6){ref-type="fig"}C). As expected, in the group of mice bearing tumors of MGC 80-3-LV-miR-647/SRF cells, 100% (8 of 8), 87.5% (7 of 8) and 75% (6 of 8) of mice had intestinal, hepatic and abdominal wall metastases, respectively (Figure [6](#F6){ref-type="fig"}C).

Lastly, the miR-647 expression in primary tumors of three groups was detected by qPCR, and the SRF and MYH9 expression in primary tumors and their metastatic nodules (4 intestinal metastases, 2 hepatic metastases and 2 abdominal wall metastases per group) were detected by IHC (Figure [S8](#SM1){ref-type="supplementary-material"}A-B and S9A-B). The qPCR data showed that LV-miR-647/vector group and LV-miR-647/SRF group had significantly higher levels of miR-647 expression, and there was no obviously different between these changes*in vivo* and the data from cell lines used for orthotropic implantation (Figure [S8](#SM1){ref-type="supplementary-material"}A). Meanwhile, the IHC data showed SRF and MYH9 expression was negatively correlated with miR-647 expression (Figure [S8](#SM1){ref-type="supplementary-material"}B). Although the SRF expression levels in randomly chosen metastatic nodules had no significantly difference between LV-miR-647/vector group and LV-miR-647/SRF group, there was expected tendency in two groups. Besides, all primary tumors and metastatic lesions were confirmed by HE staining (Figure [S8](#SM1){ref-type="supplementary-material"}G). These results further suggested that miR-647 inhibited tumor metastasis*in vivo* by downregulating SRF expression.

Agomir-647 and CCG-1423 synergistically inhibited GC metastasis *in vivo*
-------------------------------------------------------------------------

Since CCG-1423 (a SRF inhibitor) [@B32], [@B34] could downregulate MYH9 expression in our study, we carried out the CCG-1423 treatment study in orthotopic-transplant nude-mouse models of GC [@B33]. Two weeks after orthotopic-transplant surgery, the mice were treated with CCG-1423 (0.15 mg/kg/d, intraperitoneally) for 2 weeks [@B34]. Then, the same procedure was repeated at six weeks after surgery. The mice were sacrificed at 2 months after surgery. As shown in Figure [6](#F6){ref-type="fig"}D-F, the tumor volumes of CCG-1423-treated group were smaller than the control group, and the metastatic nodules were also significantly less in CCG-1423-treated group. The qPCR data showed that the CCG-1423-treated group and its control group had no significantly different levels of miR-647 expression, and this expression was not obviously different with the expression of cell lines used for orthotropic implantation (Figure [S8](#SM1){ref-type="supplementary-material"}C). Meanwhile, the IHC data showed SRF expression was no significantly different between two groups, but MYH9 expression was obviously downregulated in CCG-1423-treated group (Figure [S8](#SM1){ref-type="supplementary-material"}D and S9B).

Agomir, an engineered miRNA mimic, is well confirmed to be effective in mice diseases models [@B35]-[@B37]. Since CCG-1423 and miR-647 inhibited GC migration and invasion by different targets of Rho/SRF/MYH9 axis (Figure [S10](#SM1){ref-type="supplementary-material"}), we further detected the synergistic inhibitory effect of CCG-1423 and agomir-647 on GC metastasis. The detailed procedure for constructing orthotopic-transplant nude-mouse models and drug administration were shown in Figure [S7](#SM1){ref-type="supplementary-material"}. As shown in Figure [6](#F6){ref-type="fig"}G-I, compared with DMSO-NC, CCG-1423-NC, DMSO-agomir-647 groups, the primary tumors volumes and numbers of metastatic nodules in combined treatment group (CCG-1423, 0.15 mg/kg/d, intraperitoneally; agomir-647 80mg/kg/3d, tail vein injection) were smaller and less, respectively (Figure [6](#F6){ref-type="fig"}G-I). Meanwhile, the qPCR data showed that miR-647 expression in DMSO-NC and CCG-1423-NC groups was no obviously different with its expression in cell lines used for orthotropic implantation, and miR-647 expression in primary tumors in DMSO-agomir-647 and CCG-1423-agomir-647 groups were significantly upregulated compared with its expression in DMSO-NC and CCG-1423-NC groups (Figure [S8](#SM1){ref-type="supplementary-material"}E), respectively. We also detected SRF and MYH9 protein expression in primary tumors and metastatic nodules. Firstly, SRF expression in CCG-1423-treated groups (CCG-1423-NC and CCG-1423-agomir-647 groups) was not significantly changed compared with their own controls (DMSO-NC and DMSO- agomir-647 groups), but SRF expression in agomir-647-treated groups (DMSO-agomir-647 and CCG-1423-agomir-647 groups) was significantly downregulated compared with their own controls (DMSO-NC and CCG-1423-NC groups) (Figure [S8](#SM1){ref-type="supplementary-material"}F and S9B). In addition, MYH9 expression in agomir-647-treated or CCG-1423-treated groups was downregulated compared with their respective controls. MYH9 expression was not significantly different between CCG-1423-NC and CCG-1423-agomir-647 groups. To be sure, all primary tumor, intestinal metastasis, hepatic metastasis and peritoneal metastasis were confirmed by HE staining before qPCR and IHC studies (Figure [S8](#SM1){ref-type="supplementary-material"}G). The expression levels of SRF and MYH9 were evaluated by IHC staining (Figure [S8](#SM1){ref-type="supplementary-material"}D, S8F and S9B).

Discussion
==========

Though microRNAs\' roles in cancer have been extensively studied, the significance and specific mechanism of miR-647 in cancer remains unknown. MiR-647 has been confirmed to be upregulated in Taxol-resistant ovarian cancer cells, and high expression of miR-647 was significantly associated with longer survival in chemosensitive ovarian cancer patients [@B16]. In prostate cancer, miR-647 has been reported to be one of the three genes in the predictive biomarker panel negatively associated with recurrence [@B15]. Besides, miR-647 is one of the 7 globally population-differentiated miRNAs associated with 37 diseases including GC, though the function of miR-647 is still unknown [@B17]. Meanwhile, relevant studies seemed to have different results. For example, the expression of miR-647 was found to be no difference between localized stage I non-small cell lung cancer patients with recurrence and those without recurrence [@B23]. Even due to its stable expression patterns across cases as well as the two case groups, miR-647 was suggested to be a potential reference miRNA for future stage I non-small cell lung cancer studies. Therefore, different cancers, even different stages, may have different miRNA expression profiles. Our study demonstrates that miR-647 is frequently downregulated in human GC, and functions as a tumor suppressor via SRF/MYH9 axis in GC.

In this study, we first performed qPCR in human GC tissues and corresponding normal gastric mucosa to identify miR-647 was associated with GC metastasis. Thereafter, using a series of *in vitro* and*in vivo* assays, we uncovered that miR-647 acted as an important invasion and metastasis suppressor in GC. Although miR-647 expression has been reported previously in other human cancers [@B15]-[@B17], [@B19], [@B23], ours is the first study that provides a novel and comprehensive insight into the functional role of miR-647 in GC metastasis and Rho-mediated signal pathways (Figure [S10](#SM1){ref-type="supplementary-material"}).

We confirmed that miR-647 was frequently downregulated in GC and significantly associated with local invasion, advanced clinical stage and lymph node-metastasis. After validating miR-647 acts as a metastasis-associated miRNA *in vitro* and *in vivo*, we performed a bioinformatics search for potential mRNAs targeted by miR-647 and carried out pathway enrichment analysis for miR-647-associated signal pathways and finally focused on Rho-mediated signal pathways due to its consentaneous function in cancer metastasis. Intriguingly, by qPCR and Luciferase reporter assays, SRF and MYH9, which are involved in Rho-mediated signal pathways and predicted to be potential miR-647 targets, were confirmed to be direct and indirect downstream targets of miR-647 in GC cells, respectively.

We found miR-647 directly targeted SRF mRNA and thus regulated Rho-mediated signaling pathways in GC cells. Rho signaling is strongly implicated in cancer metastasis [@B38], and this is generally thought to reflect direct effects on the cytoskeleton [@B39]. In addition to the direct cytoplasmic role of Rho effectors in cytoskeletal regulation, Rho GTPases also control activity of MAL/MRTF-A and MKL2/MRTF-B, which are transcriptional co-activators of SRF [@B40], [@B41]. SRF is an important regulator of genes through binding to the sequence CC(A/T)~6~GG termed the CArG box [@B42], which is involved in immediate early and tissue-specific gene expression, proliferation, differentiation, apoptotic and cancer metastasis [@B25], [@B28], [@B42]. Recently, SRF has been reported to be upregulated in GC and modulate the epithelial to mesenchymal transition by regulating miR-199a-5p expression [@B28]. However, little is known about the mechanism why SRF is overexpressed in GC tissues. In this study, we found miR-647, which was significantly downregulated in GC, could lead to the loss of inhibition of SRF via 3\'UTR of SRF mRNA. The expression of miR-647 is also negatively associated SRF levels in GC tissue samples. In addition, our study also confirmed that MYH9 was a directly target of SRF in GC cells. MYH9, known as non-muscle myosin heavy chain IIA, was a known effector of Rho-ROCK signaling pathway and frequently found to be upregulated in GC [@B27], [@B43]. In our study, forced change of miR-647 expression not only led to SRF but also MYH9 dysregulation. Overexpression of MYH9 in LV-miR-647-infected GC cells could increase cells\' migration and invasion. Thus, MYH9 was a critical downstream molecule of SRF in GC cells.

Currently, it is urgent to uncover a treatment strategy for GC metastasis, especially peritoneal metastasis. Our *in vitro* results showed that miR-647/SRF/MYH9 axis could effectively inhibit GC metastasis. MicroRNAs are thought to be promising next generation therapeutic targets in human diseases [@B44], [@B45]. Moreover, agomir is an engineered miRNA mimic, and has been well confirmed to be effective in mice diseases models [@B35]-[@B37]. CCG-1423, an inhibitor of Rho/MKL1/SRF signaling, has been used to improve glucose uptake and tolerance in insulin-resistant mice [@B34]. We further used the combined treatment strategy of agomiR-647 and CCG-1423 *in vivo*, which suppressed GC invasion and migration in different targets of miR-647/SRF/MYH9 axis. The proliferation and metastasis of orthotopic-transplant nude-mouse models of GC were dramatically inhibited. This synergistically inhibitory effect *in vivo* strengthened the potential clinically significance of miR-647/SRF/MYH9 axis in GC metastasis.

Our study has a few caveats. Since one miRNA often targets to many genes to regulate cell behavior, other molecules might also contribute to the invasion and metastasis suppressing effect of miR-647. ZAK, one of the predicted genes, was a factor of aggressiveness in cancer cells [@B46]. Our study found that the expression of ZAK mRNA was not significantly upregulated in AGS cells treated with miR-647 inhibitor, though its significant upregulation in MGC 80-3 cells treated with miR-647 mimics. Moreover, though miR-647 is negatively correlated with overall survival of GC patients, the potential clinical application of miR-647 remains a subject for further study. Whether it can be detected in patients\' body fluids and serve as a diagnostic indicator are still unknown.

In conclusion, miR-647 is a potent tumor metastasis suppressor in the GC cells, and its migration and invasion inhibitory effects are, in part, mediated through its downstream target gene, SRF. MiR-647 may have a therapeutic potential to suppress GC metastasis by inhibiting Rho associated SRF/MYH9 signaling pathway.
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![**MiR-647 is downregulated in gastric cancer tissues and associated with the migration and invasion of gastric cancer cells.** (A) Expression of miR-647 was determined by qPCR in 109 human gastric cancer tissues, which was normalized against an endogenous U6 RNA control. \*\*\**p*\<0.001. (B) Relative miR-647 levels of GC and normal tissues measured by qPCR were shown using pie chart and waterfall plot. The fold change of relative miR-647 expression (T/N) \>2 or \<1/2 was defined as significant. For waterfall plot, the fold change of relative miR-647 expression (log~2~\[T/N\]) \>1 or \<-1 was defined as significant. (C) The relationship between miR-647 expression and clinical stages, lymph node-metastasis or local invasion. \**p*\<0.05; \*\**p*\<0.01. (D) Expression of miR-647 in 5 normal human gastric mucosa tissues, 5 GC cell lines and 3 colorectal cancer cell lines was analyzed by qPCR. (E and F) Expression of miR-647 in transfected MGC 80-3, MKN45 and AGS cell lines were analyzed by qPCR. \*\*\**p*\<0.001. (G and H) The 3D migration and invasion changes of different MGC 80-3 cells were tested using transwell chamber migration assay and invasion assay. Cell 2D migration was tested using monolayer wound healing assay. \*\*\**p*\<0.001.](thnov07p3338g001){#F1}

![**MiR-647 involves in Rho-associated signal pathway and negatively regulates SRF and MYH9 in gastric cancer cell lines.** (A) Bioinformatics prediction of potential miR-647 targets by 4 common miRNA databases. Part of the genes associated with cell motility were showed and Rho-associated genes were marked as red. (B) Pathway enrichment analysis of miR-647 target genes predicted in the miRBase Targets database (<http://microrna.sanger.ac.uk/targets>). Analysis was performed using version 4 of the database and miRGator. Cell motility-associated signal pathways were listed. (C) Expression of Rho-associated genes were analyzed in MGC 80-3 and AGS by qPCR. U6 served as an internal control. \*\*\*p\<0.001. (D-E) Expression of SRF and MYH9 proteins in 5 normal gastric mucosa tissues and 5 gastric cancer cell lines was analyzed by western blot and followed grayscale value analysis. GAPDH served as an internal control. (F) Western blot analysis was used to detect the expression level of SRF and MYH9 in MGC 80-3 and MKN45 cells after infection with miR-647 expressing or control lentivirus. GAPDH served as an internal control. (G) Western blot analysis was used to detect the expression changes of SRF and MYH9 in MGC 80-3-LV-miR-647 and MKN45-LV-miR-647 cells after infection with miR-647 inhibitors or its negative control (INC). GAPDH served as an internal control.](thnov07p3338g002){#F2}

![**MiR-647 inhibits the migration and invasion of gastric cancer cell lines by directly targeting to SRF mRNA, which indirectly suppresses MYH9 expression.** (A) Potential miR-647 binding sequences in the 3\'UTR of SRF and MYH9 mRNAs predicted by TargetScan and miRanda databases. (B and C) Relative luciferase activity was analyzed after the described reporter plasmids (pGV306-3\'UTR) or mock reporter plasmid (pGV306) were transfected into LV-miR-647 or LV-NC stably expressed MGC 80-3 and AGS (MGC 80-3-LV-miR-647 and AGS-LV-miR-647). The firefly luciferase activity was normalized to Renilla luciferase activity. \*\*\**p*\<0.001. (D to E) Dual-luciferase reporter assay was used to confirm SRF targeted to the promoter of MYH9 gene. \*\*\**p*\<0.001. (F) ChIP-qPCR analysis of SRF binding to the MYH9 promoter region in MGC 80-3 and AGS cells. RNA polymerase II (RNAPII) was used as a positive control. The fold enrichment over the IgG control is represented (mean ± SD; \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001). (G) Illustration of SRF protein targeting to the CArG box of MYH9 promoter. (H) Western blot analysis was used to detect the expression changes of SRF and MYH9 proteins followed by transfecting miR-647-overexpressed gastric cancer cell lines with SRF plasmid (SRF) or MYH9 plasmid (MYH9). GAPDH served as an internal control. (I) Cell 3D migration and invasion were tested using transwell chamber migration assay and invasion assay. AGS-LV-miR-647 transfected with SRF plasmid (SRF), MYH9 plasmid (MYH9) and vectors were used. Each bar represents the mean ± SD. \*\*\**p*\<0.001.](thnov07p3338g003){#F3}

![**Expression of miR-647 is inversely correlated with the expression levels of SRF and MYH9 in gastric cancer samples.**(A) Immunohistochemical staining of SRF protein in 109 paired of gastric cancer and their corresponding nontumorous tissues. Original magnification, 100×. (B) Statistical analysis of SRF expression according to the scoring (chi-square test; \*\*\**p*\<0.001.). (C) Correlation between SRF expression and miR-647 levels in the 109 gastric cancer tissue samples. \*\*\**p*\<0.001. (D) miR-647 expression patterns in human gastric cancer tissues and normal adjacent epithelial tissues as determined by *in situ* hybridization. Original magnification, 100× and 200×. DIG labeled LNA probes for U6 and scramble were used as positive and negative controls, respectively. (E and F) Expression associations of miR-647 with SRF and MYH9 expression in 109 GC patients. Two representative cases are shown (E). Original magnification, 200×. The percentage of specimens showing low or high miR-647 expression in relation to the expression levels of SRF and MYH9 (F); \**p*\<0.05. (G) Kaplan-Meier survival analysis of miR-647 expression in patients with gastric cancer (log-rank test).](thnov07p3338g004){#F4}

![**SRF/MYH9 signaling increases gastric cancer cell lines invasion and its activity is associated with poor survival in gastric cancer patients.** (A) Western blot and qPCR analyses were used to detect the expression changes of SRF and MYH9 in MGC 80-3 cells infected with SRF siRNA2 plasmid or vector control, which were selected with neomycin. (B) Western blot and qPCR analysis were used to detect SRF and MYH9 expression in the SRF knocked down MGC 80-3 cells (MGC 80-3-SRF-KD) infected with SRF plasmid or control. \*\*\**p*\<0.001. (C) Cell 3D invasion was tested using transwell chamber invasion assay (Matrigel-coated membrane). MGC 80-3 transfected with SRF siRNA2 plasmid, SRF plasmid and their corresponding vector controls were detected. CCG-1423 (7.5μmol/L) and its control Dimethyl sulfoxide (DMSO) were used to detect their influences on gastric cancer cell invasion. \*\*\**p*\<0.001; \*\**p*\<0.01. (D) Western blot and qPCR analysis were used to detect the expression changes of SRF and MYH9 in the above MGC 80-3 cells. (E) Subcellular localization of SRF and MYH9 proteins in gastric cancer cell lines (MGC 80-3 and MKN45) and gastric cancer tissues were determined by confocal immunofluorescence microscopy. (F to I) The coordinate expression of SRF and MYH9 in GC patients. TMA analysis of SRF and MYH9 in primary human GC tissues (n=90) and adjacent normal tissues (F). Original magnification, 35× and 200×. Kaplan-Meier survival analysis of SRF and MYH9 expression (G) in patients with gastric cancer (log-rank test) were performed. Spearman rank correlation analysis was performed based on the IHC expression score of SRF and MYH9 from the TMA (H). Linear regression analysis of SRF and MYH9 was performed based on the RNA-seq data from TCGA (I).](thnov07p3338g005){#F5}

![**Agomir-647 and CCG-1423 synergistically inhibit tumor growth and metastasis of gastric cancer *in vivo*.**(A-C) *In vivo* gastric cancer tumourigenesis analysis in the xenograft nude mouse models using gastric cancer cells (LV-NC/vector, LV-miR-647/vector and LV-miR-647/SRF). (A) White-light images of orthotopic tumors, intestinal, hepatic and peritoneal metastases of mice. Yellow arrows indicated metastatic nodules. Primary tumor volumes (B) and numbers of metastatic intestinal, hepatic and peritoneal nodules (C) per group were analyzed. (D-F) CCG-1423 (0.15 mg/kg/d, intraperitoneally) or vehicle alone (DMSO) was used to treat orthotopic-transplant nude-mouse for 4 weeks (2 procedures). Primary tumor volumes (E) and numbers of metastatic intestinal, hepatic and peritoneal nodules (F) per group were analyzed. (G-I) CCG-1423 (2 weeks per procedure, 2 procedures in all) and miR-647 agomir (80mg/kg/3d, tail vein injection, 5 times per procedure, 2 procedures) were combined to treat orthotopic-transplant nude-mice. Primary tumor volumes (H) and numbers of metastatic intestinal, hepatic and peritoneal nodules (I) per group were analyzed. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. a, primary tumor; b, intestinal metastatic nodules; c, hepatic metastatic nodules; d, peritoneal metastatic nodules.](thnov07p3338g006){#F6}

###### 

Univariate and Multivariate Analysis of Different Prognostic Parameters for GC Patients

                                       Cohort 1                      Cohort 2                          
  ------------------------------------ --------------------- ------- ---------- ---------------------- -------
  **Univariate Analysis**                                                                              
  Gender (male vs female)              1.120 (0.654-1.919)   0.680              1.034 (0.603-1.773)    0.903
  Age (years) (\<59 vs ≥59)            1.073 (0.629-1.830)   0.795              1.211 (0.706-2.077)    0.486
  Tumor size (cm) (\<5.5 vs ≥5.5)      1.247 (0.732-2.126)   0.417              1.616 (0.968-2.699)    0.067
  Location (C/B vs A/W)^c^             0.909 (0.528-1.567)   0.733              0.637 (0.377-1.077)    0.092
  Histological grade (W/M vs P/U)^d^   0.526 (0.310-0.891)   0.017              2.465 (1.367-4.447)    0.003
  pT status (T1/T2 vs T3/T4)           1.172 (0.620-2.215)   0.626              3.726 (1.347-10.308)   0.011
  pN status (N0 vs N1-3)               2.516 (1.190-5.320)   0.016              2.199 (1.139-4.249)    0.019
  pM status (M0 vs M1)                 2.101 (1.086-4.065)   0.027              2.829 (1.375-5.822)    0.005
  AJCC stage (I/II vs III/IV)          2.057 (1.106-3.824)   0.023              3.462 (1.936-6.191)    0.000
  miR-647 expression (low vs high)     0.451 (0.233-0.871)   0.018                                     
  SRF expression (low vs high)         2.090 (1.141-3.826)   0.017              2.426 (1.327-4.435)    0.004
  MYH9 expression (low vs high)        1.972 (1.077-3.608)   0.028              2.497 (1.345-4.634)    0.004
  **Multivariate Analysis I**                                                                          
  Histological grade (W/M vs P/U)^d^   0.450 (0.263-0.772)   0.004                                     
  AJCC stage (I/II vs III/IV)          1.883 (1.009-3.514)   0.047                                     
  miR-647 expression (low vs high)     0.388 (0.198-0.762)   0.006                                     
  **Multivariate Analysis II**                                                                         
  Histological grade (W/M vs P/U)^d^   0.453 (0.245-0.728)   0.004              1.915 (1.054-3.479)    0.033
  AJCC stage (I/II vs III/IV)          1.788 (0.956-3.344)   0.069              2.881 (1.597-5.198)    0.000
  SRF expression (low vs high)         2.321 (1.245-4.327)   0.008              1.922 (1.046-3.533)    0.035
  **Multivariate Analysis III**                                                                        
  Histological grade (W/M vs P/U)^d^   0.517 (0.304-0.877)   0.014              1.940 (1.065-3.535)    0.030
  AJCC stage (I/II vs III/IV)          1.831 (0.979-3.422)   0.058              2.886 (1.596-5.220)    0.000
  MYH9 expression (low vs high)        1.910 (1.037-3.518)   0.038              2.120 (1.136-3.956)    0.018

^a^Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using univariate or multivariate Cox proportional hazards regression in SPSS.

^b^*p* values were calculated using univariate or multivariate Cox proportional hazards regression in SPSS. p values \< 0.05 were considered to indicate statistical significance

^c^C, cardia; B, body; A, antrum; W, whole

^d^W, well; M, moderate; P, poor; U, undifferentiated
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